Betamethasone
Beta-val, Betamethasone, Betamethasone /, Betamethasone / Betamethasone, Celestone, Dermabet, Diprolene, Enstilar, Sernivo, Taclonex, Uticort, Valnac, Wynzora (betamethasone) is a small molecule pharmaceutical. Betamethasone was first approved as Celestone on 1982-01-01. It is used to treat atopic dermatitis, facial dermatoses, foot dermatoses, hand dermatoses, and inflammation amongst others in the USA. The pharmaceutical is active against glucocorticoid receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Beta-val, Betamethasone, Dermabet, Diprolene, Sernivo, Valnac (discontinued: Alphatrex, Beta-val, Betaderm, Betamethasone, Betatrex, Celestone, Diprolene, Diprosone, Luxiq, Uticort, Valisone)
CombinationsBetamethasone betamethasone, Calcipotriene betamethasone, Celestone soluspan, Clotrimazole betamethasone, Enstilar, Taclonex, Wynzora (discontinued: Calcipotriene betamethasone, Calcipotriene bethamethasone, Clotrimazole betamethasone, Lotrisone)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Betamethasone valerate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BETA-VAL | Cosette Pharmaceuticals | N-018642 RX | 1983-03-24 | 1 products |
| BETAMETHASONE VALERATE | Fougera Pharmaceuticals | N-018861 RX | 1983-08-31 | 1 products, RLD, RS |
| BETAMETHASONE VALERATE | Fougera Pharmaceuticals | N-018865 RX | 1983-08-31 | 1 products, RLD, RS |
| BETAMETHASONE VALERATE | Fougera Pharmaceuticals | N-018866 RX | 1983-08-31 | 1 products, RLD, RS |
Show 11 discontinued
Betamethasone acetate
+
Betamethasone sodium phosphate
Betamethasone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CELESTONE | Merck & Co | N-014215 DISCN | 1982-01-01 | 1 products |
| CELESTONE | Merck & Co | N-012657 DISCN | 1982-01-01 | 1 products |
| CELESTONE | Merck & Co | N-014762 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Betamethasone sodium phosphate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CELESTONE | Merck & Co | N-017561 DISCN | 1982-01-01 | 1 products, RLD |
Hide discontinued
Betamethasone benzoate
Betamethasone dipropionate
+
Calcipotriene
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ENSTILAR | LEO Pharma | N-207589 RX | 2015-10-16 | 1 products, RLD, RS |
| TACLONEX | LEO Pharma | N-021852 RX | 2006-01-09 | 1 products, RLD, RS |
| TACLONEX | LEO Pharma | N-022185 RX | 2008-05-09 | 1 products, RLD, RS |
| WYNZORA | MC2 Therapeutics | N-213422 RX | 2020-07-20 | 1 products, RLD, RS |
Betamethasone dipropionate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BETAMETHASONE DIPROPIONATE | Fougera Pharmaceuticals | N-019137 RX | 1984-06-26 | 1 products, RLD, RS |
| BETAMETHASONE DIPROPIONATE | Fougera Pharmaceuticals | N-019141 RX | 1984-09-04 | 1 products, RLD, RS |
| DIPROLENE | Organon | N-018741 RX | 1983-07-27 | 1 products, RLD, RS |
| SERNIVO | Primus Pharmaceuticals | N-208079 RX | 2016-02-05 | 1 products, RLD, RS |
Show 11 discontinued
Betamethasone dipropionate
+
Clotrimazole
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LOTRISONE | Merck & Co | N-020010 DISCN | 2000-12-08 | 1 products, RLD |
| LOTRISONE | Organon | N-018827 DISCN | 1984-07-10 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| amolg a | unapproved drug other | 2019-03-15 |
| beta 1 kit | ANDA | 2024-10-17 |
| betalido kit | unapproved drug other | 2024-12-31 |
| betaloan suik | unapproved drug other | 2024-12-31 |
| betamethasone dipropionate 0.05% / niacinamide 4% | unapproved drug other | 2019-05-20 |
| betamethasone clotrimazole | ANDA | 2009-10-27 |
| betamethasone dipropionate | New Drug Application | 2025-09-29 |
| betamethasone dipropionate 0.05% / minoxidil 5% | unapproved drug other | 2019-04-24 |
| betamethasone dipropionate 0.05% / minoxidil 5% / niacinamide 2% / pentoxifylline 0.5% | unapproved drug other | 2019-05-08 |
| betamethasone dipropionate betamethasone dipropionate | 2007-10-09 |
Show 22 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| psoriasis | EFO_0000676 | D011565 | L40 |
| atopic dermatitis | EFO_0000274 | D003876 | L20 |
| pruritus ani | — | D011538 | L29.0 |
| inflammation | MP_0001845 | D007249 | — |
| facial dermatoses | — | D005148 | — |
| seborrheic dermatitis | — | D012628 | L21 |
| foot dermatoses | — | D005533 | — |
| hand dermatoses | — | D006229 | — |
| scalp dermatoses | — | D012536 | — |
| leg dermatoses | — | D007868 | — |
Show 5 more
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Betamethasone Dipropionate / Calcipotriene, Wynzora, Mc2 | |||
| 11696919 | 2039-03-18 | DP | |
| 10265265 | 2027-09-27 | DP | |
| Betamethasone Dipropionate / Calcipotriene, Enstilar, Leo Pharma As | |||
| 9119781 | 2031-06-10 | DP | U-1761, U-2627 |
| 9566286 | 2031-06-10 | DP | |
| 10130640 | 2031-06-10 | DP | |
| 10617698 | 2031-06-10 | DP | |
| 10660908 | 2031-06-10 | DP | U-2627 |
| 10682364 | 2031-06-10 | DP | |
| 10688108 | 2031-06-10 | U-2627 | |
| 10716799 | 2031-06-10 | DP | |
| Betamethasone Dipropionate, Sernivo, Primus Pharms | |||
| 9364485 | 2030-08-31 | DP | U-1858 |
| 9433630 | 2030-08-31 | DP | U-1858 |
| 9439911 | 2030-08-31 | DP | U-1858 |
| 9655907 | 2030-08-31 | DP | U-1858 |
| 9775851 | 2030-08-31 | DP | U-1858 |
| 9877974 | 2030-08-31 | DP | U-1858 |
| 10179137 | 2030-08-31 | DP | U-1858 |
ATC Codes
A: Alimentary tract and metabolism drugs
— A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents
— A07E: Intestinal antiinflammatory agents
— A07EA: Corticosteroids acting locally
— A07EA04: Betamethasone
C: Cardiovascular system drugs
— C05: Vasoprotectives
— C05A: Agents for treatment of hemorrhoids and anal fissures for topical use
— C05AA: Corticosteroids, topical for treatment of hemorrhoids and anal fissures
— C05AA05: Betamethasone
D: Dermatologicals
— D07: Corticosteroids, dermatological preparations
— D07A: Corticosteroid dermatological preparations, plain
— D07AC: Corticosteroids, potent (group iii)
— D07AC01: Betamethasone
— D07B: Corticosteroids, combinations with antiseptics
— D07BC: Corticosteroids, potent, combinations with antiseptics
— D07BC01: Betamethasone and antiseptics
— D07C: Corticosteroids, combinations with antibiotics
— D07CC: Corticosteroids, potent, combinations with antibiotics
— D07CC01: Betamethasone and antibiotics
— D07X: Corticosteroids, other combinations
— D07XC: Corticosteroids, potent, other combinations
— D07XC01: Betamethasone
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H02: Corticosteroids for systemic use
— H02A: Corticosteroids for systemic use, plain
— H02AB: Glucocorticoids, systemic
— H02AB01: Betamethasone
R: Respiratory system drugs
— R01: Nasal preparations
— R01A: Decongestants and other nasal preparations for topical use
— R01AD: Corticosteroid nasal preparations for topical use
— R01AD06: Betamethasone
— R03: Drugs for obstructive airway diseases
— R03B: Other drugs for obstructive airway diseases, inhalants in atc
— R03BA: Glucocorticoid inhalants for obstructive airway disease
— R03BA04: Betamethasone
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01B: Antiinflammatory agents, ophthalmologic
— S01BA: Corticosteroid ophthalmologic antiinflammatory agents, plain
— S01BA06: Betamethasone
— S01BB: Corticosteroids and mydriatics in combination
— S01BB04: Betamethasone and mydriatics
— S01C: Antiinflammatory agents and antiinfectives in combination
— S01CA: Corticosteroids and antiinfectives in combination, opthalmologic
— S01CA05: Betamethasone and antiinfectives
— S01CB: Corticosteroids/antiinfectives/mydriatics in combination
— S01CB04: Betamethasone
— S02: Otologicals
— S02B: Corticosteroid otologicals
— S02BA: Corticosteroids
— S02BA07: Betamethasone
— S03: Ophthalmological and otological preparations
— S03B: Corticosteroid ophthalmologic and otologic preparations
— S03BA: Corticosteroids
— S03BA03: Betamethasone
— S03C: Corticosteroids and antiinfectives in combination, opthalmologic and otologic
— S03CA: Corticosteroids and antiinfectives in combination
— S03CA06: Betamethasone and antiinfectives
Clinical
Clinical Trials
494 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | — | — | 2 | — | — | 2 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Betamethasone |
| INN | betamethasone |
| Description | Betamethasone is a glucocorticoid, a 20-oxo steroid, a 21-hydroxy steroid, a 17alpha-hydroxy steroid, a fluorinated steroid, an 11beta-hydroxy steroid, a 3-oxo-Delta(1),Delta(4)-steroid, a primary alpha-hydroxy ketone and a tertiary alpha-hydroxy ketone. It has a role as an anti-inflammatory drug, an anti-asthmatic agent and an immunosuppressive agent. It derives from a hydride of a pregnane. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO |
Identifiers
| PDB | — |
| CAS-ID | 378-44-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL632 |
| ChEBI ID | 3077 |
| PubChem CID | 9782 |
| DrugBank | DB00443 |
| UNII ID | 9842X06Q6M (ChemIDplus, GSRS) |
Target
Agency Approved
NR3C1
NR3C1
Organism
Homo sapiens
Gene name
NR3C1
Gene synonyms
GRL
NCBI Gene ID
Protein name
glucocorticoid receptor
Protein synonyms
Nuclear receptor subfamily 3 group C member 1, nuclear receptor subfamily 3 group C member 1 variant hGR-B(54), nuclear receptor subfamily 3 group C member 1 variant hGR-B(77), nuclear receptor subfamily 3 group C member 1 variant hGR-B(93), nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
Uniprot ID
Mouse ortholog
Nr3c1 (14815)
glucocorticoid receptor (Q61629)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Estimated US medical usage
Betamethasone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Betamethasone
+
Calcipotriene
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Betamethasone
+
Clotrimazole
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 16,956 documents
View more details
Safety
Black-box Warning
Black-box warning for: Bl-c kit, Marbeta 25 kit, Marbeta l kit
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
16,188 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use